A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →. With Regeneron Pharmaceuticals.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
312actual
Sites
138
Countries
Argentina, Brazil, Canada +17
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-20 | actual | When the study began enrolling |
| Primary completion | 2025-09-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-02 | actual | The whole study's end, after follow-up |
| First posted | 2024-02-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Bronchiectasis
Interventions
- Drug: Itepekimab (SAR440340) — also filed as REGN3500
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFAnnualized rate of moderate or severe Pulmonary exacerbations (PEs) over the treatment period
measured Baseline up to End of Treatment (EOT) (24-52 weeks)
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed